AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKEPRNewsWire • 08/31/26
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/29/26
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis StudyZacks Investment Research • 08/27/26
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?Investors Business Daily • 08/27/26
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTSPRNewsWire • 08/27/26
White House to announce new drug pricing deals with biotechs, Bloomberg News reportsReuters • 08/26/26
Bet on These Biotech ETFs as Innovation Drives Market-Beating GrowthZacks Investment Research • 08/20/26
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)The Motley Fool • 08/14/26
Amgen gains after strong quarterly results and continued product momentumProactive Investors • 08/05/26